Skip to main content
  • Explore Research
  • Learn About Clinical Trials
  • Pediatric Clinical Trials
  • Clinical Trial Video Series
  • Featured Research
  • Find a Clinical Trial
  • Clinical Trial Patient Stories
  • Get Involved
  • Research Updates
  • Resources for Professionals
  • Newsletter Archives
  • Talk to a Specialist

Featured Research

The Crohn's & Colitis Foundation collaborates with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below, and the Crohn's & Colitis Foundation does not endorse any particular study.

For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.

Clinical Trials Phases
  • (X) Phase 3 (19)

Current Results: 19 entries

Safety and Feasibility of Oligofructose-Enriched Inulin in Pediatric Inflammatory Bowel Disease. Short title: The TII Trial: Treating IBD with Inulin (TII)
Phase 3
Sponsor: Children's Hospital of Philadelphia and Crohn's and Colitis Foundation
Description:
  • To evaluate the effect of the prebiotic fiber inulin on the microbiome of children with IBD who have subclinical disease activity (patients with no symptoms but elevated fecal calprotectin)
  • To evaluate the efficacy of the prebiotic fiber inulin in reducing gut inflammation (fecal calprotectin) in IBD

 

Recruiting Now »
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Investigational Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis
Phase 3
Sponsor: Gilead Primis
Description:

The primary objective of this study is to evaluate whether investigational cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

Recruiting Now »
A clinical research study evaluating the safety and effectiveness of the investigational medicine for treating ulcerative colitis in children and in young adults.
Phase 3
Sponsor: Janssen
Description:

The purpose of the PURSUIT 2 study is to see if an investigational medicine is safe and effective for treating children and young adults with UC.

Recruiting Now »
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Phase 3
Sponsor: Arena Pharmaceuticals, Inc.
Description:

The primary objective is to assess the efficacy of study drug on clinical remission in subjects with moderately to severely active ulcerative colitis (UC) after 12 and 52 weeks of treatment. 

Click here to learn more

 

 

Recruiting Now »
SEAVUE: A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naive Subjects with Moderately-to-Severely Active Crohn's Disease
Phase 3
Sponsor: Janssen Scientific Affairs, LLC
Description:

The purpose of this study is to compare the effects (both good and bad) of both Stelara and Humira for those that have Crohn's Disease.

Recruiting Now »
A Study to Assess the Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Phase 3
Sponsor: AbbVie
Description:

The purpose of this study is to evaluate the efficacy and safety of different doses of risankizumab and determine how well it works in patients with moderate to severe Crohn’s disease.

Recruiting Now »
A Study of the Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease
Phase 3
Sponsor: AbbVie
Description:

The purpose of this study is to evaluate the efficacy and safety of different doses of risankizumab and determine how well it works in patients with moderate to severe Crohn’s disease.

Recruiting Now »
YELLOWSTONE - Open Label Study (3204) - A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
Phase 3
Sponsor: Celgene International II Sarl
Description:

Demonstrate the long-term safety and efficacy of ozanimod for the treatment of subjects with moderate to severely active CD.

Recruiting Now »
YELLOWSTONE - Induction Study (RPC01-3202) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.
Phase 3
Sponsor: Celgene International II Sarl
Description:

The primary objective of this study is to evaluate the efficacy of oral ozanimod compared with placebo on the induction of clinical remission.

Recruiting Now »
YELLOWSTONE - Induction Study (RPC01-3201) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.
Phase 3
Sponsor: Celgene International II Sarl
Description:

The primary objective of this study is to evaluate the efficacy of oral ozanimod compared with placebo on the induction of clinical remission.

Recruiting Now »

Pagination

  • Current page 1
  • Page 2
  • Next page ››
  • Last page Last »
If you are interested in listing your trial on the Featured Research page, please contact [email protected]

Browser not supported

Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options:

Google Chrome

Download Chrome

Firefox

Download Firefox

Safari (macOS 10.8+ only)

Download Safari